CC BY 4.0 · Surg J (N Y) 2018; 04(04): e226-e234
DOI: 10.1055/s-0038-1675827
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Oncological Outcomes of Open Radical Retropubic Prostatectomy in Ireland: A Single Surgeon's 5-Year Experience

Stefanie M. Croghan
1   Department of Urology, The Mater Misericordiae University Hospital, Eccles Street, Dublin, Ireland
Deep Mudit Matanhelia
2   Department of Urology, St. Vincent's University Hospital, Elm Park, Dublin, Ireland
Ann T. Foran
1   Department of Urology, The Mater Misericordiae University Hospital, Eccles Street, Dublin, Ireland
David J. Galvin
1   Department of Urology, The Mater Misericordiae University Hospital, Eccles Street, Dublin, Ireland
2   Department of Urology, St. Vincent's University Hospital, Elm Park, Dublin, Ireland
3   Department of Urology, St. Vincent's Private Hospital, Elm Park, Dublin, Ireland
› Author Affiliations
Further Information

Publication History

29 July 2018

08 October 2018

Publication Date:
28 November 2018 (online)


Objectives There is a little published data on the outcomes of radical prostatectomy in the Irish context. We aimed to determine the 5-year oncological results of open radical retropubic prostatectomy (RRP) performed by a single surgeon following appointment.

Methods A retrospective review of RRPs performed between 2011 and 2016 was conducted. Patient demographics, preoperative parameters (clinical stage on digital rectal exam, prostate-specific antigen (PSA) levels, biopsy Gleason's score and MRI [magnetic resonance imaging] findings), pathological variables (T-stage, Gleason's score, nodal status, and surgical margin status), and treatment decisions (lymphadenectomy or adjuvant radiotherapy) were recorded. Oncological outcome at last follow-up was ascertained.

Results 265 patients underwent RRP between 2011 and 2016. Median age was 62 years (range: 41–74). Mean follow-up was 32.24 months (range: 8–72) months. Pathological disease stage was T2 in 170/265 (64.15%), T3a in 65/265 (24.53%), and T3b in 30/265 (11.32%). Final Gleason's score was upgraded from diagnostic biopsy in 16.35% (43/263) and downgraded in 27% (71/263). Pelvic lymph node dissection was performed in 44.25% (118/265) patients. A positive surgical margin (PSM) was seen in 26/170 (15.2%) patients with T2 disease and in 45/95 (47.37%) patients with T3 disease. Of the 265 patients, 238 (89.81%) were disease-free at last follow-up, of whom 24/238 (10.08%) had received adjuvant and 17/238 (7.14%) received salvage radiotherapy. Adjuvant/salvage treatment was ongoing in 19/265 (7.17%) of patients.

Conclusion Good oncological outcomes of RRP in the Irish context are seen in this 5-year review, with the vast majority of patients experiencing biochemical-free survival at most recent follow-up.

Financial Support


  • References

  • 1 The National Cancer Registry. Cancer in Ireland 1994–2014: annual report of the National Cancer Registry;2016. Available from: . Accessed January 16, 2018
  • 2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. , et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49 (06) 1374-1403
  • 3 The National Cancer Registry. Cancer factsheet: prostate;2015. Available from: . Accessed January 16, 2018
  • 4 Oon SF, Cullen IM, Moran D. , et al. The effect of a rapid access prostate cancer clinic on prostate cancer patient and disease characteristics, primary treatment and surgical workload. Ir J Med Sci 2014; 183 (02) 241-247
  • 5 The Second National Cancer Forum. A strategy for cancer control in Ireland;2006. Available from: . Accessed January 4, 2018
  • 6 Stephenson AJ, Scardino PT, Eastham JA. , et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98 (10) 715-717
  • 7 Tan PH, Cheng L, Srigley JR. , et al; ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 5: surgical margins. Mod Pathol 2011; 24 (01) 48-57
  • 8 Babaian K, Truong M, Cetnar J. , et al. Analysis of urological procedures in men who died from prostate cancer using a population-based approach. BJU Int 2013; 111 (3, Pt B): E65-E70
  • 9 Lake AM, He C, Wood Jr DP. Focal positive surgical margins decrease disease-free survival after radical prostatectomy even in organ-confined disease. Urology 2010; 76 (05) 1212-1216
  • 10 Bouchier-Hayes DM, Clancy KX, Canavan K, O'Malley PJ. Initial consecutive 125 cases of robotic assisted laparoscopic radical prostatectomy performed in Ireland's first robotic radical prostatectomy centre. Ir J Med Sci 2012; 181 (01) 21-25
  • 11 Yaxley JW, Coughlin GD, Chambers SK. , et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016; 388 (10049): 1057-1066
  • 12 Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 2012; 188 (06) 2219-2224
  • 13 Alemozaffar M, Sanda M, Yecies D, Mucci LA, Stampfer MJ, Kenfield SA. Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the health professionals follow-up study. Eur Urol 2015; 67 (03) 432-438
  • 14 Schiavina R, Borghesi M, Dababneh H. , et al. Survival, continence and potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes. Eur J Surg Oncol 2014; 40 (12) 1716-1723
  • 15 Liu XJ, Liu L, Chang K, Ye DW, Zheng YF, Yao XD. Risk factors of perioperative complications in patients undergoing radical retropubic prostatectomy: a ten-year experience. J Huazhong Univ Sci Technolog Med Sci 2017; 37 (03) 379-383
  • 16 Simon RM, Howard LE, Moreira DM. , et al. Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. Int J Urol 2017; 24 (08) 618-623
  • 17 Thomas C, Pfirrmann K, Pieles F. , et al. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy. BJU Int 2012; 109 (02) 214-219
  • 18 Sfoungaristos S, Perimenis P. Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer. Can Urol Assoc J 2013; 7 (1,2): E93-E97
  • 19 Mortezavi A, Keller EX, Poyet C. , et al. Clinical impact of prostate biopsy undergrading in an academic and community setting. World J Urol 2016; 34 (10) 1481-1490
  • 20 Athanazio D, Gotto G, Shea-Budgell M, Yilmaz A, Trpkov K. Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology 2017; 70 (07) 1098-1106
  • 21 Pourmand G, Gooran S, Hossieni SR. , et al. Correlation of preoperative and radical prostatectomy gleason score: examining the predictors of upgrade and downgrade results. Acta Med Iran 2017; 55 (04) 249-253
  • 22 Hsieh TF, Chang CH, Chen WC, Chou CL, Chen CC, Wu HC. Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer. J Chin Med Assoc 2005; 68 (04) 167-171
  • 23 Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. ; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40 (02) 244-252
  • 24 Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology 2012; 79 (03) 626-631
  • 25 Heering M, Berg KD, Brasso K, Iversen P, Røder MA. Radical prostatectomy in Denmark: survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up. Surg Oncol 2017; 26 (01) 21-27
  • 26 Leyh-Bannurah SR, Karakiewicz PI, Dell'Oglio P. , et al. Comparison of 11 active surveillance protocols in contemporary european men treated with radical prostatectomy. Clin Genitourin Cancer 2017; 16 (01) e141-e149
  • 27 van der Poel HG, Wit EM, Acar C. , et al; Sentinel Node Prostate Cancer Consensus Panel Group members. Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU Int 2017; 120 (02) 204-211
  • 28 Bianchi L, Gandaglia G, Fossati N. , et al. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. Urologia 2017; 84 (01) 9-19
  • 29 De Vergie S, Gaschignard N, Baron M. , et al. [Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection]. Prog Urol 2018; 28 (01) 25-31
  • 30 Mottet N, Bellmunt J, Bolla M. , et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71 (04) 618-629
  • 31 Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 2018; 36 (01) 15-20
  • 32 National Comprehensive Cancer Network2017. Available from: . Accessed January 4, 2018
  • 33 D'Amico AV, Whittington R, Malkowicz SB. , et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280 (11) 969-974
  • 34 Wang EH, Yu JB, Gross CP. , et al. Association between surgeon and hospital characteristics and lymph node counts from radical prostatectomy and pelvic lymph node dissection. Urology 2015; 85 (04) 890-895
  • 35 Abdollah F, Sun M, Suardi N. , et al. Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. Urol Oncol 2013; 31 (08) 1497-1503
  • 36 Karakiewicz PI, Eastham JA, Graefen M. , et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5,831 patients. Urology 2005; 66 (06) 1245-1250
  • 37 Swindle P, Eastham JA, Ohori M. , et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005; 174 (03) 903-907
  • 38 Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154 (05) 1818-1824
  • 39 Yossepowitch O, Briganti A, Eastham JA. , et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 2014; 65 (02) 303-313
  • 40 Mauermann J, Fradet V, Lacombe L. , et al. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1,712 adjuvant treatment-naive pT2–4 N0 radical prostatectomy patients. Eur Urol 2013; 64 (01) 19-25
  • 41 Lee JW, Ryu JH, Kim YB, Yang SO, Lee JK, Jung TY. Do positive surgical margins predict biochemical recurrence in all patients without adjuvant therapy after radical prostatectomy?. Korean J Urol 2013; 54 (08) 510-515
  • 42 Ploussard G, Agamy MA, Alenda O. , et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. BJU Int 2011; 107 (11) 1748-1754
  • 43 Chapin BF, Nguyen JN, Achim MF. , et al. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis 2018; 21 (02) 221-227
  • 44 Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152 (5, Pt 2): 1837-1842
  • 45 Negishi T, Kuroiwa K, Hori Y. , et al. Predictive factors of late biochemical recurrence after radical prostatectomy. Jpn J Clin Oncol 2017; 47 (03) 233-238
  • 46 Liesenfeld L, Kron M, Gschwend JE, Herkommer K. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy. J Urol 2017; 197 (01) 143-148